Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 27Gynecologic 4Genitourinary 2Other solid neoplasm 1Other 1Head & Neck 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Letrozole × Genitourinary × Clear all
NCT07288359 2026-06-04

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT07570966 2026-05-06

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Not yet recruiting
217 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡